MedTrace Logo

Slow-Release Oral Morphine for the Treatment of Opioid Use Disorder

NCT03948464 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2022-02-10

No results posted yet for this study

Summary

This is a non-inferiority randomized clinical trial that will compare slow release oral morphine vs methadone as a second line oral treatment for opioid use disorder.

Conditions

  • Opioid-Related Disorders
  • Opiate Substitution Treatment
  • Morphine
  • Methadone
  • Fentanyl

Interventions

DRUG

Slow release oral morphine (SROM)

Slow release oral morphine is an opioid agonist. Slow release oral morphine will be administered via daily witnessed ingestion at designated community pharmacies.

DRUG

Methadone

Methadone is an opioid agonist. Methadone will be administered via daily witnessed ingestion at designated community pharmacies.

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Vancouver Foundation

    collaborator OTHER

  • Mayne Pharma International Pty Ltd

    collaborator INDUSTRY

  • M. Eugenia Socias

    lead OTHER

Principal Investigators

  • M. Eugenia Socias, MD, MSc · BC Centre on Substance Use

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-06
Primary Completion
2020-06-01
Completion
2020-06-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03948464 on ClinicalTrials.gov